Verastem Inc. (NASDAQ: VSTM) is a clinical stage biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. Our most advanced programs target the phosphoinositide-3-kinase (PI3K) and Focal Adhesion Kinase (FAK) pathways.
February 7, 2017
Verastem to Present at 19th Annual BIO CEO & Investor Conference
January 26, 2017
Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
January 19, 2017
Verastem Announces Executive Leadership Appointments and Changes
Major advances in cancer treatment have led to significant improvements in efficacy. However, this benefit does not extend to all patients. Challenges in the tumor microenvironment may both support tumor survival, and inhibit anti-tumor activity of cancer therapies and adaptive immune response.